Arcturus stock: buy or sell?

ARCT stock price: $10.74 9.37% At close on December 6th, 2019

Updated on:
December 6th, 2019

0

Arcturus shares broke up the simple moving average line of 100d today and closed at $10.74. On Tuesday ARCT collapsed a scary -7.19%.

Arcturus Therapeutics Ltd. operates as an RNA medicines company. Its RNA therapeutics platforms could be applied in various types of RNA medicines, including small interfering RNA, messenger RNA, replicon RNA, antisense RNA, microRNA, and gene editing therapeutics.

Should I buy Arcturus stock?

You can't be a successful trader if you don't follow a methodolgy or system that assist you in choosing companies and the correct market timing. Trading strategies are meant for helping you in the decision process of what stocks to pick and when is the best moment to buy them. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.

None of our preferred buy setups matches with Arcturus stock situation right now, hence this is not a suitable entry point.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This doesn't mean ARCT will slide in coming sessions, or it will not rise higher. Simply, it doesn't match our recommended trading systems.

Is Arcturus Therapeutics stock a buy?

Everyday, hundreds of stock ratings are posted by financial analysts to indicate a particular stock's attractiveness. At Stocks2.com, we detected 5 ratings published for ARCT stock in the last month.

The general sentiment of these ratings is bullish for ARCT stock, with 5 positive ratings.
Is ARCT a good stock to buy?
DateAnalyst / BrokerPrevious ratingCurrent rating
2019-8-7HC Wainwrightn/aBuy
2019-6-20Chardan Capitaln/aBuy
2019-4-5HC Wainwrightn/aBuy
2019-3-19Chardan Capitaln/aBuy
2019-2-19Laidlawn/aBuy

Arcturus stock analysis

Daily outlook

Arcturus shares broke up the simple moving average line of 100d today and closed at $10.74, rocketed a 9.37%.

Arcturus crossed up the SMA line of 100d today and closed at $10.74. ARCT is retaking the upward trend marking a new rising bottom heading to break out over $11.42.

ARCT stock chart (daily)

Weekly outlook

After boosting an amazing 13.34% in a week last week, Arcturus closed this week at $10.74 and eased a godawful -3.85%. By mid November ARCT collapsed a bloodcurdling -10.08% in just one week.

Since mid June when SMA20w and SMA40w crossed up, ARCT price gained $4.39 per share (69.13%). Since price and SMA40w lines crossed up late May, ARCT climbed $4.51 (72.39%).

ARCT stock chart (weekly)

Arcturus stock price history

Arcturus IPO was on March 1st, 2012 at $6.00 per share1. Since then, ARCT stock grew a 79.00%, with a yearly average of 11.30%. If you had invested $1,000 in Arcturus stock in 2012, it would worth $790.00 today.

1: Adjusted price after possible price splits or reverse-splits.

Arcturus stock historical price chart

ARCT stock reached 52-week highs on July at $15.50, and all-time highs 2013-10-04 with a price of 188.72.

Arcturus stock price target is $17.30

Nobody can reliably foresee how stock prices may evolve in the future. However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. You should not follow the analysts' ARCT stock price predictions in the hope that they will be met as they may be wrong and not met. For the last month we found 4 price forecasts for Arcturus stock:
ARCT stock price predictions
DateAnalyst / BrokerActionPrevious targetCurrent targetDiff
2019-8-7HC WainwrightRaises Target$16.00$18.0012.5%
2019-6-20Chardan CapitalSet Price Targetn/a$18.00-
2019-4-5HC WainwrightInitiatesn/a$15.00-
2019-3-19Chardan CapitalReiteratesn/a$18.00-
(in average)$16.00$17.308.0%
Moving in a range from $18.00 and $15.00, the price target for Arcturus stock is $17.30. In average, analysts' outlook on ARCT price target is positive, improving the prediction by a 8.00% from previous estimations.

Financials and fundamental analysis

Earnings date and Earnings per Share

Arcturus failed experts on March when it posted an Earnings per Share (EPS) of $-0.10 when the market consensus was $-0.62.
ARCT earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise
2017-Q1-n/a-0.89n/a
2017-Q2-n/a-0.94n/a
2017-Q3-n/an/an/a
2017-Q42018-04-04n/an/an/a
2018-Q12018-07-03n/an/an/a
2018-Q22018-10-01n/a-0.5n/a
2018-Q32018-11-07-0.35-0.42n/a
2018-Q42019-03-18-0.62-0.1n/a
2019-Q1-n/an/an/a
2019-Q2-n/an/an/a

Annual financial results

In 2018, Arcturus Therapeutics annual revenues rocketed an exceptional 21.20% to $15.75 M dollars from $13.00 marked in 2017. When comparing 2018 vs 2017, however, profit margin (that is, the net income divided by revenues) plunged a -54.42% to -138.29%.

ARCT annual Sales and Income evolution
YearSalesYoYIncome/(margin)YoY
2016$20 M-$-24.60 M-120.7%-
2017$13 M-36.23%$-10.90 M-83.9%-55.69%
2018$16 M21.20%$-21.79 M-138.3%99.83%

Quarterly financial results

Arcturus Therapeutics reported $7.58 million in sales for 2018-Q4, a 121.36% up compared to previous quarter. Reported quarter income marked $-1.01 M with a profit margin of -13.34%. Profit margin skyrocketed a 110.90% compared to previous quarter when profit margin was -124.25%. When comparing turnover to same quarter last year, Arcturus sales marked an astounding increase and climbed a 275.10%. Looking back to recent quarterly results, Arcturus Therapeutics posted 3 positive quarters in a row.
ARCT quarterly Sales and Income evolution
QuarterSales1QoQ2Income1/(margin)QoQ2
2017-Q2$4 M-$-1.10 M-29.2%-
2017-Q3$3 M-12.36%$-3.18 M-96.4%189.08%
2017-Q4$2 M-38.71%$-5.28 M-261.4%66.19%
2018-Q2$2 M18.12%$-9.95 M-417.0%88.45%
2018-Q3$3 M43.46%$-4.25 M-124.2%-57.26%
2018-Q4$8 M121.36%$-1.01 M-13.3%-76.23%

Arcturus ownership

When you are planning to buy a company, it's worth to review its ownership structure.

Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Arcturus Therapeutics, 46.92% of all outstanding shares are owned by its staff.

In case of Arcturus stock, 14.51% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for ARCT stock account 0.00%, no big difference from last month.

The following table compares ownership indicators for other stocks related to Arcturus Therapeutics:

ARCT
Market cap$162.5 M
Total shares15.1 M
Float shares9.3 M
  - Institutional holdings (%)14.5%
  - Insider holdings (%)46.9%
Shares in short selling0.0%

Arcturus summary

Friday, December 6th, 2019
Open$9.91
Close$10.74
Day range$9.91 - $11.29
Previous close$9.82
Session gain9.37%
Average true range$0.79
50d mov avg$10.26
100d mov avg$10.73
200d mov avg$8.88
Daily patternlb02a
Weekly pattern

Arcturus performance

Stocks performance is always measured in comparision to the market or competitors and related stocks in the same industry. We chose as the bechmarking frame for Arcturus Therapeutics stock.
Stock3m6m12m
ARCTArcturus Therapeu...1.03%62.24%95.63%

Arcturus competitors

Unfortunately, we could not find any public company that could be defined as Arcturus Therapeutics competitor. This doesn't mean Arcturus Therapeutics does not have any competitor in the market, it's just we could not detected it.